The tubes and collection kits meet the requirements of the European In-Vitro Diagnostic Devices Directive, and the company can now commercialize the devices throughout Europe.
Fluidigm logged $26.4 million in revenues compared to $29.0 million a year ago and well short of analysts' consensus estimate of $28.7 million.
Akadeum is currently developing a tool that involves microbubbles to deplete background molecules from circulating tumor cells in liquid biopsies.
The firm will use the net proceeds for research and development, marketing, and general corporate purposes to help commercialize its LX Analyzer technology.
The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The partners will use Biolidics' circulating tumor cell retrieval system to evaluate the cells' utility as biomarkers of patient response to cancer treatment.
Fluidigm will develop a microfluidic device for single-cell measurement of epigenetic changes under a broader $27.8 million DARPA-funded project.
Among the claims, NeuMoDx has alleged that BD was kept up to date on the firm's technology as it was developed and that one of the patents was duplicitously expanded by BD.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
Stephen Hahn, the nominee to lead the US Food and Drug Administration, underwent a Senate confirmation hearing yesterday, the Washington Post reports.
The US Food and Drug Administration has approved an RNA interference drug to treat acute hepatic porphyria.
Gizmodo looks over the past decade of consumer DNA testing to find the field to be lacking.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.